{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:10:51Z","timestamp":1778584251293,"version":"3.51.4"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s13300-026-01861-9","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:26:34Z","timestamp":1776227194000},"page":"671-684","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing Type 2 Diabetes Management in Iraq: Expert Consensus on Initiation and Intensification of Insulin-Based Treatment Options"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4233-8088","authenticated-orcid":false,"given":"Charles","family":"Saab","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8083-6024","authenticated-orcid":false,"given":"Abbas Ali","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0368-4383","authenticated-orcid":false,"given":"Abbas Mahdi","family":"Rahmah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7058-1573","authenticated-orcid":false,"given":"Delman Raoof","family":"Al-Attar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3912-8103","authenticated-orcid":false,"given":"Haidar Fadhil","family":"Al-Rubay\u2019e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3132-1758","authenticated-orcid":false,"given":"Haider Ayad","family":"Alidrisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7926-3660","authenticated-orcid":false,"given":"Hussein Ali","family":"Nwayyir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8183-6683","authenticated-orcid":false,"given":"Mahmood Shakir","family":"Khudhair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0340-2519","authenticated-orcid":false,"given":"Mazyar Jabbar","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1397-0204","authenticated-orcid":false,"given":"Salim Marzouq","family":"Al-Ibrahimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9477-8814","authenticated-orcid":false,"given":"Taha Othman","family":"Mahwi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"1861_CR1","doi-asserted-by":"publisher","first-page":"117955142094223","DOI":"10.1177\/1179551420942232","volume":"13","author":"M Abusaib","year":"2020","unstructured":"Abusaib M, Ahmed M, Nwayyir HA, Alidrisi HA, Al-Abbood M, Al-Bayati A, et al. Iraqi Experts Consensus on the Management of Type 2 Diabetes\/Prediabetes in Adults. Clin Med Insights Endocrinol Diabetes. 2020;13:1179551420942232.","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"1861_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2147\/DMSO.S59652","volume":"7","author":"AA Mansour","year":"2014","unstructured":"Mansour AA, Al-Maliky AA, Kasem B, Jabar A, Mosbeh KA. Prevalence of diagnosed and undiagnosed diabetes mellitus in adults aged 19 years and older in Basrah, Iraq. Diabetes Metab Syndr Obes. 2014;7:139\u201344.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"1861_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1900\/RDS.2023.19.14","volume":"19","author":"H Vargas-Uricoechea","year":"2023","unstructured":"Vargas-Uricoechea H, Frias JP, Vargas-Sierra HD. Fixed-ratio combinations (basal insulin plus GLP-1RA) in Type 2 Diabetes. An analytical review of pivotal clinical trials. Rev Diabet Stud. 2023;19(1):14\u201327.","journal-title":"Rev Diabet Stud"},{"key":"1861_CR4","doi-asserted-by":"crossref","unstructured":"Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32 Suppl 1(Suppl 1):S62\u20137.","DOI":"10.2337\/dc09-S062"},{"key":"1861_CR5","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.2147\/DMSO.S319895","volume":"14","author":"J Reed","year":"2021","unstructured":"Reed J, Bain S, Kanamarlapudi V. A review of current trends with Type 2 Diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives. Diabetes Metab Syndr Obes. 2021;14:3567\u2013602.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"1861_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176275","author":"U Galicia-Garcia","year":"2020","unstructured":"Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21176275.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1861_CR7","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in Type 2 Diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753\u201386.","journal-title":"Diabetes Care"},{"key":"1861_CR8","unstructured":"Iraq Diabetes country report 2000 \u2014 2050."},{"issue":"12","key":"1861_CR9","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"41","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D\u2019Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in Type 2 Diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669\u2013701.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"1861_CR10","first-page":"S158","volume":"47","author":"Pharmacologic Approaches to Glycemic Treatment","year":"2024","unstructured":"Pharmacologic Approaches to Glycemic Treatment. Standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S158\u201378.","journal-title":"Diabetes Care"},{"issue":"2","key":"1861_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.5603\/cd.104242","volume":"14","author":"D Alidrisi","year":"2025","unstructured":"Alidrisi D, Alidrisi H, Hadi A. Effect of short-term basal insulin initiation in newly diagnosed Type 2 Diabetes on one-year glycemic control: Prospective cohort, interventional, two-arm study. Clin Diabetol. 2025;14(2):74\u201380.","journal-title":"Clin Diabetol"},{"issue":"5","key":"1861_CR12","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s13300-022-01247-7","volume":"13","author":"SB Harris","year":"2022","unstructured":"Harris SB, Parente EB, Karalliedde J. Clinical use of Insulin Glargine 300 U\/mL in adults with Type 2 Diabetes: Hypothetical case studies. Diabetes Ther. 2022;13(5):913\u201330.","journal-title":"Diabetes Ther"},{"issue":"9","key":"1861_CR13","volume":"13","author":"HA Alidrisi","year":"2021","unstructured":"Alidrisi HA, Bohan A, Mansour AA. Barriers of doctors and patients in starting insulin for Type 2 Diabetes Mellitus. Cureus. 2021;13(9):e18263.","journal-title":"Cureus"},{"issue":"11","key":"1861_CR14","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1007\/s12325-018-0819-5","volume":"35","author":"J Okemah","year":"2018","unstructured":"Okemah J, Peng J, Qui\u00f1ones M. Addressing clinical inertia in Type 2 Diabetes Mellitus: A review. Adv Ther. 2018;35(11):1735\u201345.","journal-title":"Adv Ther"},{"issue":"9 Suppl 1","key":"1861_CR15","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.amjmed.2013.06.012","volume":"126","author":"SA Ross","year":"2013","unstructured":"Ross SA. Breaking down patient and physician barriers to optimize glycemic control in Type 2 Diabetes. Am J Med. 2013;126(9 Suppl 1):S38-48.","journal-title":"Am J Med"},{"issue":"11","key":"1861_CR16","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.2337\/diacare.28.11.2673","volume":"28","author":"M Peyrot","year":"2005","unstructured":"Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, et al. Resistance to insulin therapy among patients and providers: Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28(11):2673\u20139.","journal-title":"Diabetes Care"},{"issue":"5","key":"1861_CR17","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/j.1464-5491.2012.03605.x","volume":"29","author":"M Peyrot","year":"2012","unstructured":"Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012;29(5):682\u20139.","journal-title":"Diabet Med"},{"issue":"6","key":"1861_CR18","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.diabet.2017.06.003","volume":"43","author":"G Reach","year":"2017","unstructured":"Reach G, Pechtner V, Gentilella R, Corcos A, Ceriello A. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab. 2017;43(6):501\u201311.","journal-title":"Diabetes Metab"},{"issue":"3","key":"1861_CR19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/dme.12592","volume":"32","author":"A Zafar","year":"2015","unstructured":"Zafar A, Stone MA, Davies MJ, Khunti K. Acknowledging and allocating responsibility for clinical inertia in the management of type 2 diabetes in primary care: a qualitative study. Diabet Med. 2015;32(3):407\u201313.","journal-title":"Diabet Med"},{"issue":"2","key":"1861_CR20","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s13300-018-0375-7","volume":"9","author":"L Berard","year":"2018","unstructured":"Berard L, Antonishyn N, Arcudi K, Blunden S, Cheng A, Goldenberg R, et al. Insulin matters: a practical approach to basal insulin management in type 2 diabetes. Diabetes Ther. 2018;9(2):501\u201319.","journal-title":"Diabetes Ther"},{"issue":"7","key":"1861_CR21","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1503\/cmaj.110779","volume":"184","author":"AN Lau","year":"2012","unstructured":"Lau AN, Tang T, Halapy H, Thorpe K, Yu CH. Initiating insulin in patients with type 2 diabetes. CMAJ. 2012;184(7):767\u201376.","journal-title":"CMAJ"},{"issue":"1","key":"1861_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/jama.2017.7115","volume":"318","author":"W Lane","year":"2017","unstructured":"Lane W, Bailey TS, Gerety G, Gumprecht J, Philis-Tsimikas A, Hansen CT, et al. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial. JAMA. 2017;318(1):33\u201344.","journal-title":"JAMA"},{"issue":"1","key":"1861_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jama.2017.7117","volume":"318","author":"C Wysham","year":"2017","unstructured":"Wysham C, Bhargava A, Chaykin L, de la Rosa R, Handelsman Y, Troelsen LN, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial. JAMA. 2017;318(1):45\u201356.","journal-title":"JAMA"},{"issue":"8","key":"1861_CR24","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa1615692","volume":"377","author":"SP Marso","year":"2017","unstructured":"Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, et al. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med. 2017;377(8):723\u201332.","journal-title":"N Engl J Med"},{"issue":"7","key":"1861_CR25","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1111\/dom.14372","volume":"23","author":"GB Bolli","year":"2021","unstructured":"Bolli GB, Cheng A, Charbonnel B, Aroda VR, Westerbacka J, Bosnyak Z, et al. Glycaemic control and hypoglycaemia risk with insulin glargine 300\u2009U\/mL and insulin degludec 100\u2009U\/mL in older participants in the BRIGHT trial. Diabetes Obes Metab. 2021;23(7):1588\u201393.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"1861_CR26","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1111\/dom.14043","volume":"22","author":"M Haluz\u00edk","year":"2020","unstructured":"Haluz\u00edk M, Cheng A, M\u00fcller-Wieland D, Westerbacka J, Bosnyak Z, Lauand F, et al. Differential glycaemic control with basal insulin glargine 300 U\/mL versus degludec 100 U\/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial. Diabetes Obes Metab. 2020;22(8):1369\u201377.","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"1861_CR27","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/dom.12485","volume":"17","author":"R Ritzel","year":"2015","unstructured":"Ritzel R, Roussel R, Bolli GB, Vinet L, Brulle-Wohlhueter C, Glezer S, et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U\/ml versus glargine 100 U\/ml in people with type 2 diabetes. Diabetes Obes Metab. 2015;17(9):859\u201367.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"1861_CR28","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2337\/dc16-0684","volume":"40","author":"RM Bergenstal","year":"2017","unstructured":"Bergenstal RM, Bailey TS, Rodbard D, Ziemen M, Guo H, Muehlen-Bartmer I, et al. Comparison of Insulin Glargine 300 Units\/mL and 100 Units\/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections. Diabetes Care. 2017;40(4):554\u201360.","journal-title":"Diabetes Care"},{"key":"1861_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001518","author":"A Perez","year":"2020","unstructured":"Perez A, Carrasco-S\u00e1nchez FJ, Gonz\u00e1lez C, Segu\u00ed-Ripoll JM, Trescol\u00ed C, Ena J, et al. Efficacy and safety of insulin glargine 300 U\/mL (Gla-300) during hospitalization and therapy intensification at discharge in patients with insufficiently controlled Type 2 Diabetes: Results of the phase IV COBALTA trial. BMJ Open Diabetes Res Care. 2020. https:\/\/doi.org\/10.1136\/bmjdrc-2020-001518.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"Suppl 1","key":"1861_CR30","first-page":"S125","volume":"45","author":"Pharmacologic Approaches to Glycemic Treatment","year":"2022","unstructured":"Pharmacologic Approaches to Glycemic Treatment. Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S125\u201343.","journal-title":"Diabetes Care"},{"issue":"4","key":"1861_CR31","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1089\/dia.2015.0290","volume":"18","author":"MC Riddle","year":"2016","unstructured":"Riddle MC, Bolli GB, Home PD, Bergenstal RM, Ziemen M, Muehlen-Bartmer I, et al. Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U\/mL in People with Type 2 Diabetes. Diabetes Technol Ther. 2016;18(4):252\u20137.","journal-title":"Diabetes Technol Ther"},{"key":"1861_CR32","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.diabres.2017.03.003","volume":"126","author":"M Hassanein","year":"2017","unstructured":"Hassanein M, Al-Arouj M, Hamdy O, Bebakar WMW, Jabbar A, Al-Madani A, et al. Diabetes and Ramadan: Practical guidelines. Diabetes Res Clin Pract. 2017;126:303\u201316.","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"1861_CR33","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.diabet.2018.02.002","volume":"44","author":"R Roussel","year":"2018","unstructured":"Roussel R, Ritzel R, Bo\u00eblle-Le Corfec E, Balkau B, Rosenstock J. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U\/mL vs glargine 100U\/mL in T2DM. Diabetes Metab. 2018;44(5):402\u20139.","journal-title":"Diabetes Metab"},{"issue":"5","key":"1861_CR34","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3111\/13696998.2011.610852","volume":"14","author":"C Fidler","year":"2011","unstructured":"Fidler C, Elmelund Christensen T, Gillard S. Hypoglycemia: an overview of fear of hypoglycemia, quality-of-life, and impact on costs. J Med Econ. 2011;14(5):646\u201355.","journal-title":"J Med Econ"},{"issue":"10","key":"1861_CR35","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.2337\/dc18-0559","volume":"41","author":"J Rosenstock","year":"2018","unstructured":"Rosenstock J, Cheng A, Ritzel R, Bosnyak Z, Devisme C, Cali AMG, et al. More Similarities Than Differences Testing Insulin Glargine 300 Units\/mL Versus Insulin Degludec 100 Units\/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial. Diabetes Care. 2018;41(10):2147\u201354.","journal-title":"Diabetes Care"},{"issue":"7258","key":"1861_CR36","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"IM Stratton","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405\u201312.","journal-title":"BMJ"},{"issue":"15","key":"1861_CR37","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577\u201389.","journal-title":"N Engl J Med"},{"issue":"11","key":"1861_CR38","volume":"14","author":"AA Mansour","year":"2022","unstructured":"Mansour AA, Rahmah A, Khudhair M. Management of Type 2 Diabetes With Insulin Glargine-100 in Iraq in a Real-Life Observation. Cureus. 2022;14(11):e31164.","journal-title":"Cureus"},{"key":"1861_CR39","doi-asserted-by":"crossref","unstructured":"Summary of Revisions: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Supplement_1):S5-s10.","DOI":"10.2337\/dc24-SDIS"},{"issue":"2","key":"1861_CR40","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/jdi.12884","volume":"10","author":"Y Kawaguchi","year":"2019","unstructured":"Kawaguchi Y, Sawa J, Sakuma N, Kumeda Y. Efficacy and safety of insulin glargine 300 U\/mL vs insulin degludec in patients with type 2 diabetes: a randomized, open-label, cross-over study using continuous glucose monitoring profiles. J Diabetes Investig. 2019;10(2):343\u201351.","journal-title":"J Diabetes Investig"},{"key":"1861_CR41","doi-asserted-by":"crossref","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S19-s40.","DOI":"10.2337\/dc23-S002"},{"issue":"5","key":"1861_CR42","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.eprac.2023.02.001","volume":"29","author":"SL Samson","year":"2023","unstructured":"Samson SL, Vellanki P, Blonde L, Christofides EA, Galindo RJ, Hirsch IB, et al. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm - 2023 Update. Endocr Pract. 2023;29(5):305\u201340.","journal-title":"Endocr Pract"},{"issue":"11","key":"1861_CR43","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.2337\/dc16-0917","volume":"39","author":"J Rosenstock","year":"2016","unstructured":"Rosenstock J, Aronson R, Grunberger G, Hanefeld M, Piatti P, Serusclat P, et al. Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes inadequately controlled on oral agents: the LixiLan-O randomized trial. Diabetes Care. 2016;39(11):2026\u201335.","journal-title":"Diabetes Care"},{"issue":"11","key":"1861_CR44","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.2337\/dc16-1495","volume":"39","author":"VR Aroda","year":"2016","unstructured":"Aroda VR, Rosenstock J, Wysham C, Unger J, Bellido D, Gonz\u00e1lez-G\u00e1lvez G, et al. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. Diabetes Care. 2016;39(11):1972\u201380.","journal-title":"Diabetes Care"},{"issue":"5","key":"1861_CR45","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1080\/03007995.2018.1541790","volume":"35","author":"L Blonde","year":"2019","unstructured":"Blonde L, Anderson JE, Chava P, Dendy JA. Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes. Curr Med Res Opin. 2019;35(5):793\u2013804.","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"1861_CR46","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/S2213-8587(14)70174-3","volume":"2","author":"SC Gough","year":"2014","unstructured":"Gough SC, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2(11):885\u201393.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"1861_CR47","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.2337\/dc14-0785","volume":"37","author":"JB Buse","year":"2014","unstructured":"Buse JB, Vilsb\u00f8ll T, Thurman J, Blevins TC, Langbakke IH, B\u00f8ttcher SG, et al. Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira). Diabetes Care. 2014;37(11):2926\u201333.","journal-title":"Diabetes Care"},{"issue":"3","key":"1861_CR48","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s13300-018-0395-3","volume":"9","author":"J Meece","year":"2018","unstructured":"Meece J. Basal insulin intensification in patients with type 2 diabetes: a review. Diabetes Ther. 2018;9(3):877\u201390.","journal-title":"Diabetes Ther"},{"issue":"3","key":"1861_CR49","doi-asserted-by":"publisher","first-page":"408","DOI":"10.4103\/2230-8210.180003","volume":"20","author":"S Kalra","year":"2016","unstructured":"Kalra S, Gupta Y, Unnikrishnan AG. Flexibility in insulin prescription. Indian J Endocrinol Metab. 2016;20(3):408\u201311.","journal-title":"Indian J Endocrinol Metab"},{"issue":"12","key":"1861_CR50","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1111\/dom.13851","volume":"21","author":"E Miller","year":"2019","unstructured":"Miller E, Doshi A, Gr\u00f8n R, J\u00f3dar E, \u0150rsy P, Ranthe MF, et al. IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy. Diabetes Obes Metab. 2019;21(12):2643\u201350.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"1861_CR51","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.2337\/dc17-1600","volume":"40","author":"T Danne","year":"2017","unstructured":"Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, et al. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40(12):1631\u201340.","journal-title":"Diabetes Care"},{"issue":"9","key":"1861_CR52","first-page":"958","volume":"28","author":"S Edelman","year":"2022","unstructured":"Edelman S, Cassarino D, Kayne D, Dex T, Li X, Pasquel FJ. Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist. J Manag Care Spec Pharm. 2022;28(9):958\u201368.","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"1861_CR53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1159\/000521437","volume":"28","author":"M Hassanein","year":"2022","unstructured":"Hassanein M, Al Dahi W, Radhi HT, AIMahfouz A, Al Kaabi J, Alshammari A, et al. Expert-group practical advice on insulin initiation and titration for patients with Type 2 Diabetes in the Gulf Region. Dubai Diabetes Endocrinol J. 2022;28(2):45\u201355.","journal-title":"Dubai Diabetes Endocrinol J"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01861-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01861-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01861-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:21:41Z","timestamp":1778581301000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-026-01861-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1861"],"URL":"https:\/\/doi.org\/10.1007\/s13300-026-01861-9","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Charles Saab has participated in research, and has acted as a advisor and served as B2peaker for Amgen, Astra Zeneca, MSD, Novo Nordisk, Sanofi, Novartis, Genentech, Merck Serono, J&J, Pharmaline, Ei Lilli, BI, Chiesi, BPI, Hikma, Takeda, Sandoz, Algorithm, Pfizer. Abbas Ali Mansour has acted as a consultant\/advisor and speaker for Novo Nordisk, Sanofi and Servier. Abbas Mahdi Rahmah has acted as a consultant\/advisor and speaker for Novo Nordisk, Sanofi, Servier, Merck, Ajanta and AstraZeneca. Delman Raoof Al-Attar acted as a speaker for many international companies like Sanofi, Eli Lilly, Novo Nordisk, Merck, MSD, Boehringer Ingelheim and AstraZeneca. Haidar Fadhil Al-Rubay\u2019e has acted as a consultant\/advisor and speaker for Sanofi, Merck, Novo Nordis and AstraZeneca, Eli Lilly. He has also contributed to the Iraqi Consensus of Diabetes supported by Merck. Haider Ayad Alidrisi has acted as a consultant\/advisor for Sanofi,Merck and Novo Nordisk. Also, act as an active speaker for Boehringer Ingelheim, Sanofi, AstraZeneca, Merck, Novo Nordisk, Eli Lilly. Hussein Ali Nwayyir has acted as a speaker for Sanofi, Novo Nordisk and AstraZeneca, and has served as a consultant\/advisor for Sanofi. He has also participated in writing the Iraqi oral diabetes mellitus treatment guideline in collaboration with Merck. Mahmood Shakir Khudhair has acted as a speaker for Hikma, AstraZeneca, Novo Nordisk, Sanofi, Merck and Boehringer Ingelheim, and has served as a consultant\/advisor for Sanofi, AstraZeneca, Merck and Eli Lilly. Mazyar Jabbar Ahmed acted as a consultant\/advisor and speaker for many international companies like Sanofi, Novo Nordisk, Merck, and AstraZeneca. Salim Marzouq Al-Ibrahimi has acted as a consultant\/advisor for Sanofi in diabetes and dyslipidemia, has contributed to the Iraqi Diabetes Guideline Consensus supported by Merck, and has served as a speaker for Sanofi, Novo Nordisk, Eva Pharm and Boehringer Ingelheim. Taha Othman Mahwi has acted as a consultant\/advisor and speaker for Sanofi,Merck, Novo Nordis and AstraZeneca, He has also contributed to the Iraqi Consensus of Diabetes supported by Merck. All authors have received an honorarium from Sanofi for the Sanofi advisory board and have not received any honorarium for the publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously published studies and expert consensus discussions and does not include any new studies involving human participants or animals performed by the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}